Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M. Kirkwood, Georgina V. Long, Piotr Rutkowski et al.|Nature Medicine|2023Cited by 208
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)Georgina V. Long, John M. Kirkwood, Michele Del Vecchio et al.|SKIN The Journal of Cutaneous Medicine|2023Cited by 25
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Michele Maio, Pippa Corrie et al.|Journal of Clinical Oncology|2023Cited by 25
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).Georgina V. Long, Michele Del Vecchio, John M. Kirkwood et al.|Journal of Clinical Oncology|2023Cited by 13
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgeryJohn M. Kirkwood, Georgina V. Long, Michele Del Vecchio et al.|Future Oncology|2024Cited by 2